Fluoxetine Side Effects and Management

Introduction to Fluoxetine Side Effects

The American College of Physicians recommends being aware that fluoxetine commonly causes gastrointestinal symptoms, neurological effects, sexual dysfunction, and anxiety/nervousness, with nausea being the most frequent reason for treatment discontinuation 1, 2

Nausea and vomiting are the most frequently reported adverse effects and the leading cause of discontinuation in clinical trials, according to the American College of Physicians 1, 2
Diarrhea, constipation, dry mouth, and heartburn occur commonly, though fluoxetine has lower rates of diarrhea compared to sertraline, as noted by the American College of Physicians 1, 2
Sexual adverse events are common with fluoxetine, though absolute rates are likely underreported in clinical trials, and the American College of Physicians states that fluoxetine has lower rates of sexual dysfunction than paroxetine but higher rates than bupropion 1, 2
Fluoxetine causes less weight gain than mirtazapine or paroxetine, according to the American College of Physicians 1, 2

SSRIs including fluoxetine increase the risk of nonfatal suicide attempts, though not completed suicides, and close monitoring is essential during the first few months of treatment and following dosage adjustments, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 2, 3
The American Academy of Child and Adolescent Psychiatry recommends being aware that serotonin syndrome is a rare but potentially life-threatening condition that occurs when fluoxetine is combined with other serotonergic medications, and combination with MAOIs is absolutely contraindicated 3

The American Academy of Child and Adolescent Psychiatry suggests starting with a subtherapeutic "test" dose to help identify patients who will experience anxiety or agitation as an initial adverse effect, and the long half-life of fluoxetine allows for slower dose titration at approximately 3-4 week intervals 3
Fluoxetine has the lowest risk of discontinuation syndrome among SSRIs due to its long half-life, essentially precluding withdrawal phenomena, as noted by the American Academy of Child and Adolescent Psychiatry 3